CHRDL1 Regulates Stemness in Glioma Stem-like Cells.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
03 Dec 2022
Historique:
received: 19 10 2022
revised: 25 11 2022
accepted: 29 11 2022
entrez: 11 12 2022
pubmed: 12 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

Glioblastoma (GBM) still presents as one of the most aggressive tumours in the brain, which despite enormous research efforts, remains incurable today. As many theories evolve around the persistent recurrence of this malignancy, the assumption of a small population of cells with a stem-like phenotype remains a key driver of its infiltrative nature. In this article, we research Chordin-like 1 (CHRDL1), a secreted protein, as a potential key regulator of the glioma stem-like cell (GSC) phenotype. It has been shown that CHRDL1 antagonizes the function of bone morphogenic protein 4 (BMP4), which induces GSC differentiation and, hence, reduces tumorigenicity. We, therefore, employed two previously described GSCs spheroid cultures and depleted them of CHRDL1 using the stable transduction of a CHRDL1-targeting shRNA. We show with in vitro cell-based assays (MTT, limiting dilution, and sphere formation assays), Western blots, irradiation procedures, and quantitative real-time PCR that the depletion of the secreted BMP4 antagonist CHRDL1 prominently decreases functional and molecular stemness traits resulting in enhanced radiation sensitivity. As a result, we postulate CHRDL1 as an enforcer of stemness in GSCs and find additional evidence that high CHRDL1 expression might also serve as a marker protein to determine BMP4 susceptibility.

Identifiants

pubmed: 36497175
pii: cells11233917
doi: 10.3390/cells11233917
pmc: PMC9741078
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : LI 3687/2-1

Références

Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
Sci Rep. 2019 Oct 10;9(1):14569
pubmed: 31602000
Future Oncol. 2013 Sep;9(9):1389-96
pubmed: 23980685
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Cancers (Basel). 2019 Mar 12;11(3):
pubmed: 30871073
Trends Cancer. 2020 May;6(5):380-391
pubmed: 32348734
Mol Vis. 2008 Jun 20;14:1138-48
pubmed: 18587495
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Int J Mol Sci. 2021 Apr 20;22(8):
pubmed: 33924205
Neoplasia. 2017 Apr;19(4):261-270
pubmed: 28278424
J Clin Oncol. 2007 Sep 10;25(26):4127-36
pubmed: 17827463
Brain Res. 2013 Apr 24;1507:115-24
pubmed: 23466456
Mol Cell Biol. 2016 May 02;36(10):1509-25
pubmed: 26976638
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Cancers (Basel). 2021 Jul 16;13(14):
pubmed: 34298790
Oncogene. 2008 May 1;27(20):2897-909
pubmed: 18037961
Mol Med Rep. 2013 Apr;7(4):1143-8
pubmed: 23404565
Cancer Lett. 2013 May 28;332(2):374-82
pubmed: 21315505
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Oral Dis. 2022 May 5;:
pubmed: 35510812
PLoS One. 2012;7(8):e43628
pubmed: 22928007
Mol Cancer. 2010 Jun 01;9:135
pubmed: 20515495
Biomolecules. 2021 Jun 25;11(7):
pubmed: 34202286
Nature. 2006 Dec 7;444(7120):761-5
pubmed: 17151667
Front Oncol. 2022 Apr 14;12:862751
pubmed: 35494000
Oncotarget. 2016 Jan 5;7(1):593-609
pubmed: 26573230
Anat Cell Biol. 2015 Mar;48(1):25-35
pubmed: 25806119
J Cell Biochem. 2009 Dec 1;108(5):1031-8
pubmed: 19760641
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nature. 2016 Nov 10;539(7628):309-313
pubmed: 27806376
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cancers (Basel). 2022 Jan 11;14(2):
pubmed: 35053502
Front Surg. 2016 Apr 15;3:21
pubmed: 27148537
Cell Stem Cell. 2009 Jun 5;4(6):568-80
pubmed: 19497285
Oncol Lett. 2020 Feb;19(2):1247-1254
pubmed: 31966054
Cancer Res. 2010 Sep 1;70(17):6870-9
pubmed: 20736377
Oncogene. 2013 May 9;32(19):2433-41
pubmed: 22751114
Biomed Res Int. 2014;2014:725921
pubmed: 24834433
Clin Cancer Res. 2010 May 15;16(10):2715-28
pubmed: 20442299
Nat Cancer. 2022 Sep;3(9):1105-1122
pubmed: 35915262
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Biomol Concepts. 2010 Oct 1;1(3-4):297-304
pubmed: 25962004
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Mol Cancer Ther. 2017 Jan;16(1):156-168
pubmed: 27777286
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Sci Rep. 2022 Mar 9;12(1):4176
pubmed: 35264691

Auteurs

Inka Berglar (I)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.

Stephanie Hehlgans (S)

Department of Radiotherapy and Oncology, Goethe University Hospital, 60590 Frankfurt am Main, Germany.

Andrej Wehle (A)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.

Caterina Roth (C)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.

Christel Herold-Mende (C)

Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, INF400, 69120 Heidelberg, Germany.

Franz Rödel (F)

Department of Radiotherapy and Oncology, Goethe University Hospital, 60590 Frankfurt am Main, Germany.
German Cancer Consortium DKTK Partner site Frankfurt/Main, 60590 Frankfurt am Main, Germany.
German Cancer Research Center DKFZ, 69120 Heidelberg, Germany.
Frankfurt Cancer Institute (FCI), Theodor-Stern-Kai 7, University of Frankfurt, 60590 Frankfurt am Main, Germany.

Donat Kögel (D)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.
German Cancer Consortium DKTK Partner site Frankfurt/Main, 60590 Frankfurt am Main, Germany.
German Cancer Research Center DKFZ, 69120 Heidelberg, Germany.

Benedikt Linder (B)

Experimental Neurosurgery, Department of Neurosurgery, Neuroscience Center, Goethe University Hospital, 60590 Frankfurt am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH